Latest Morning Briefing Stories
The sweeping spending measure passed by Congress and signed by President Donald Trump last week contains lots of wins for an industry that has publicly been under attack for the past year. The success shows how formidable the health care industry remains.
And new customers totaled more than 2 million people — an increase of 36,000 from last year. That’s considered a positive sign because it reflects consumer interest. The final tally doesn’t include the millions of people who chose a health plan through state-run exchanges.
Editorial pages focus on these health topics and others.
Media outlets cover health care news from Illinois, New York, California, Wisconsin, North Carolina, Massachusetts, Texas, Florida and Minnesota.
Researchers have long been stumped about a mysterious set of symptoms that affected more than a dozen diplomats. New tests offer clues to what’s happening in their brains, even though doctors still haven’t found a cause. In other public health news: gene-editing, infertility, driving under the influence of marijuana, and more.
The tool was launched to help beneficiaries better organize their medication lists. The potential breach was contained though to about 10,000 authorized users.
A report from the Office of Inspector General for HHS found that the reforms were too narrow and weren’t implemented at all the facilities. The review came after it was revealed that the agency protected a doctor who was abusing young boys in his care for decades. Other Trump administration news comes from the CMS, Justice Department and FCC.
According to a report produced for Senate Democrats, the Consumer Product Safety Commission approved recalls in a way that actually generated more business for the company at fault. That’s because rather than getting new, safe products or refunds following a recall, consumers are often offered discount coupons for new products.
The North American trade pact is moving swiftly through Congress. The legislation is noticeably missing a provision that would have granted market exclusivity for biologics for 10 years. The removal of the protection was a big win for Democrats and a huge loss for the pharmaceutical industry. In other news: an Ebola vaccine, nerve drugs, biotech stocks, a subscription model for medication, and more.
The $1.4 trillion package contained wins for both parties. But many major health care issues — such as surprise medical bills — were left untouched. Congress faced a Friday night deadline to approve the funding to avoid a shutdown. President Donald Trump is expected to sign the legislation.
Many questions remain following the appeals court’s decision to kick the case back down to a federal district judge, but the Affordable Care Act does remain intact for now. Meanwhile, Republicans get some political breathing room as they head into the 2020 elections because it’s unlikely the lawsuit will be in front of the Supreme Court anytime soon.
With his health care proposals, Democratic presidential race late-comer Michael Bloomberg stands in middle-of-the-road ground rather than steering into the progressive lanes of the party, where universal care and “Medicare for All” are more favored.
Former Vice President Joe Biden and Sen. Bernie Sanders’ (I-Vt.) exchange started out with some teasing, but escalated into shouting and interruptions as they touched on well-worn arguments about the status quo versus the costs of “Medicare for All.” Sen. Amy Klobuchar (D-Minn.) jumped in to redirect Sanders’ anger toward congressional Republicans instead of his rival candidates. But overall, health care played a much smaller role at the final debate of the year as “Medicare for All” sinks in popularity.
Media outlets report on news from Illinois, California, Colorado, Texas, Washington, Pennsylvania, Ohio, Massachusetts, Kansas, Wyoming, Louisiana, Georgia and Missouri.
Despite the fact that buprenorphine has changed the lives of those struggling with addiction, it still doesn’t have widespread support. Some worry that the medication, an opiate itself, is just replacing one addiction with another. But as the opioid continues to devastate the country, more and more are embracing the recovery method.
ProPublica investigates how much a New Jersey plan that covers teachers paid out for specialists because it doesn’t have limits on out-of-network bills. More than 70 acupuncturists and physical therapists earned more than $200,000 in 2018 from their teacher clients alone, and one brought in more than $1 million.
Senate Majority Leader Mitch McConnell, who has outsized power in deciding the Senate’s schedule, has not slated the Senate Finance Committee’s drug pricing bill for a vote, largely because the package does not have widespread Republican support. In other pharmaceutical news: “one-and-done” therapies, generics lawsuits, and insulin costs.
“Tonight’s ruling is a chilling threat to the 130 million Americans with preexisting conditions and every other family who depends on the lifesaving protections of the Affordable Care Act,” said House Speaker Nancy Pelosi (D-Calif.). Meanwhile, insurers and other industry groups who have been living with turmoil for years over the fate of the law were concerned the decision only drags out the uncertainty. President Donald Trump heralded the ruling, vowing to protect the law’s popular provisions without giving details on how he would do so.
Congress’ decision to repeal three health law taxes was a huge win for the industry, but consumer protection issues — like surprise medical bills — were not included. Meanwhile, advocates hope that the data that might come from the gun violence funding included in the spending bill for the first time in decades will make a difference in swaying lawmakers in the future.
For one thing, Canada doesn’t produce enough drugs, nor does it seem to be on board with exporting the ones it does have to America. Beyond that, experts say President Donald Trump’s plan will have little to no impact on what consumers pay for drugs.